Monoclonal Antibody Collaboration and Licensing Deals 2019-2026

Description

The definitive benchmark for monoclonal antibody dealmaking

Monoclonal antibody partnering is driven by a well-established yet continuously evolving class of biologic therapies, with deal structures reflecting both mature development pathways and ongoing innovation in next-generation antibody formats.

This report provides a comprehensive and structured analysis of 740+ monoclonal antibody collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how monoclonal antibody deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by development stage, antibody type, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a competitive and innovation-driven biologics landscape
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within monoclonal antibody partnerships, particularly in areas involving differentiated biologics and evolving therapeutic strategies.
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark biologics transactions
Prepare for negotiations with well-defined market context
Evaluate licensing and co-development opportunities
Support internal strategy with robust, defensible data
What's included
740+ monoclonal antibody collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, therapy, and antibody type)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for monoclonal antibody dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how monoclonal antibody partnerships are structured, negotiated, and valued.

Product Code: CP21131

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in monoclonal antibody dealmaking

2.1. Introduction
2.2. Monoclonal antibody deals over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody deals by deal type
2.5. Monoclonal antibody deals by therapy area
2.6. Monoclonal antibody deals by industry sector
2.7. Deal terms for monoclonal antibody deals
- 2.7.1 Monoclonal antibody deals headline values
- 2.7.2 Monoclonal antibody deal upfront payments
- 2.7.3 Monoclonal antibody deal milestone payments
- 2.7.4 Monoclonal antibody royalty rates

Chapter 3 - Leading monoclonal antibody deals

3.1. Introduction
3.2. Top monoclonal antibody deals by value

Chapter 4 - Most active monoclonal antibody dealmakers

4.1. Introduction
4.2. Most active monoclonal antibody dealmakers
4.3. Most active monoclonal antibody deals company profiles

Chapter 5 - Monoclonal antibody contracts dealmaking directory

5.1. Introduction
5.2. Monoclonal antibody contracts dealmaking directory

Chapter 6 - Monoclonal antibody dealmaking by technology type

Deal directory
Deal directory - Monoclonal antibody deals by company A-Z
Deal directory - Monoclonal antibody deals by deal type
Deal directory - Monoclonal antibody deals by therapy area
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Monoclonal antibody deals since 2019
Figure 2: Active monoclonal antibody dealmaking activity since 2019
Figure 3: Monoclonal antibody deals by deal type since 2019
Figure 4: Monoclonal antibody deals by therapy area since 2019
Figure 5: Monoclonal antibody deals by industry sector since 2019
Figure 6: Monoclonal antibody deals with a headline value
Figure 7: Monoclonal antibody deals with an upfront value
Figure 8: Monoclonal antibody deals with a milestone value
Figure 9: Monoclonal antibody deals with a royalty rate value
Figure 10: Top monoclonal antibody deals by value since 2019
Figure 11: Most active monoclonal antibody dealmakers since 2019
Figure 12: Monoclonal antibody deals by technology type since 2019